{"content":[{"text":"Vaccines used at the CHEMPARK \n \"Highly effective and well tolerated\"","bbox":{"left":0.119267,"top":0.08417,"width":0.5478559999999999,"height":0.04155400000000001}},{"text":"CURRENTA had already announced at the beginning of March that it would \n make a vaccination offer to CHEMPARK companies and their employees. \n Now we can finally get started - even if the ordered quantities will \n probably not be fully available at first. Good reason for a conversation with \n Dr. med. Harald Bischof, Head of Medical Services at CHEMPARK, about \n vaccines.","bbox":{"left":0.117993,"top":0.142373,"width":0.764618,"height":0.099738}},{"text":"Has it already been \n decided which vaccines will \n be used at CHEMPARK? \n No. However, since we will be \n vaccinating in full compliance \n with the recommendations of \n the Standing Commission on \n Vaccination and have ordered \n the BioNTech preparation, it is \n very likely that we will receive \n exactly this vaccine - but \n perhaps not to the desired \n extent for the time being. It is \n still conceivable that we could vaccinate employees over 60 with \n AstraZeneca.","bbox":{"left":0.119267,"top":0.275407,"width":0.658066,"height":0.24940100000000004}},{"text":"So is AstraZeneca safe? \n Of course, otherwise there would be no approval.","bbox":{"left":0.119267,"top":0.541475,"width":0.49896299999999993,"height":0.033221000000000056}},{"text":"But first AstraZeneca was only allowed to give it to people under \n 65, then not at all and now only to those over 60. What should \n one believe? \n I can understand why this recommendation back-and-forth causes \n confusion and skepticism. But let's look closely! At the beginning, there \n was simply too little data to make a recommendation for people over 65 \n because the clinical trial phase, which was important for approval, had \n included very few elderly people. In the meantime, AstraZeneca has been \n used to vaccinate many millions of times in Germany alone, and the \n European Medicines Agency concludes that the vaccination benefit of this \n preparation actually increases with age. Moreover, the benefit clearly \n outweighs the extremely low risk of rare blood clot formation, even in the \n younger age groups.","bbox":{"left":0.119267,"top":0.591362,"width":0.748393,"height":0.21614299999999997}},{"text":"So no doubts with regard to Astra? \n No. As a medical professional, however, I can say: AstraZeneca's vaccine \n is highly effective and well tolerated. It reliably protects against severe or \n life-threatening courses of disease and is much less complicated to handle \n - in terms of refrigeration requirements - than the vaccines from BioNTech \n and Moderna. There is slightly worse protection against mild courses of the","bbox":{"left":0.119267,"top":0.824172,"width":0.761423,"height":0.099738}}],"images_bbox":[{"left":0.448174,"top":0.279016,"width":0.429024,"height":0.202105}],"images_bbox_not_text_overlap":[{"left":0.448174,"top":0.279016,"width":0.429024,"height":0.202105}]}